Predict your next investment

Corporation
mikrogen.de

See what CB Insights has to offer

About Mikrogen

Mikrogen is focusing on the direct and indirect detection of bacterial, viral and parasitic infections as well as autoimmune and cancer diseases.

Mikrogen Headquarter Location

Floriansbogen 2-4

Neuried, 82061,

Germany

+49 89 54801-0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mikrogen News

New Products Posted to GenomeWeb: Roche, Jumpcode Genetics, Mikrogen, More

Oct 29, 2021

Save for later Roche Avenio Tumor Tissue Comprehensive Genomic Profiling Kit Roche has launched its Avenio Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit for research use. The jointly developed project from Roche and Foundation Medicine delivers information about complex genomic signatures, including tumor mutational burden, microsatellite instability, and loss of heterozygosity, in addition to a comprehensive genomic panel. It provides an end-to-end next-generation sequencing workflow, including DNA extraction and library preparation, and delivers results by the FoundationOne Analysis Platform via Avenio Connect. The kit's gene panel is drawn from the FoundationOne companion diagnostic panel, analyzing 324 cancer-related genes across four main classes of genomic alterations and genomic signatures. It is configured to run 24 samples with results in five days on Illumina's NextSeq 500/550 RUO and NextSeq 550 Dx System in research mode. The kit is intended for laboratories to use in house and will launch in Europe, North America, Asia, and South America. Jumpcode Genomics CRISPRclean rRNA Depletion Kits Jumpcode Genomics has launched two new kits for ribosomal RNA depletion. The CRISPRclean Stranded Total RNA Prep kit with rRNA depletion offers unbiased depletion and library preparation for RNA sequencing. The CRISPRclean Plus kit depletes over 200 bacteria species and human rRNA sequences to enable identification of lower-expressed transcripts. Mikrogen T-Track SARS-CoV-2 Assay Mikrogen, a Neuried, Germany-based developer of genetically manufactured in vitro diagnostics, has introduced its research-use-only T-Track SARS-CoV-2 assay to determine T-cell-mediated immune responses. The new RT-qPCR assays detect the mRNA expression of several specific marker cytokines simultaneously. The assays require about 3 ml of heparin blood/patient, are conducive to partial automation and intermediate storage of samples, and have shown a high sensitivity in the early infection phase, the company said. For more new products and services, please visit the New Products page on our website.

Mikrogen Acquisitions

1 Acquisition

Mikrogen acquired 1 company. Their latest acquisition was Lophius Biosciences on March 09, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/9/2021

Series E

$23.84M

Acquired

1

Date

3/9/2021

Investment Stage

Series E

Companies

Valuation

Total Funding

$23.84M

Note

Acquired

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.